Clinical trials: Ovarian Cancers
Polycystic Ovary Syndrome
CANA/Met in Non-diabetic Women With PCOS
Polycystic ovary syndrome (PCOS), which is associated with hyperinsulinaemia, hyperandrogenaemia, impaired glucose metabolism and aberrant adipokines production from the adipose tissue, is a heterogeneous reproductive and…
- Trial name
- NCT04973891
- Testing
- Canagliflozin combined with metformin, metformin
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shengjing Hospital
Polycystic Ovary Syndrome
Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
Polycystic Ovary Syndrome (PCOS) is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovaries. Insulin resistance (IR) is a common feature of PCOS, and the resultant hyperinsulinemia is theorized to promote…
- Trial name
- TIN-PCOS-AOD (NCT03229408)
- Testing
- Salsalate
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
PCOS and US Cavitation
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. Women with this syndrome may have infrequent menstrual periods or amenorrhea and excess androgen levels.
- Trial name
- NCT05880550
- Testing
- ultrasound cavitation in addition to aerobic ex, aerobic exercises.
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Polycystic Ovary Syndrome, Healthy
Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism
Background: Polycystic ovary syndrome (PCOS) is as common as 5-10% of all women in Austria. PCOS women frequently present with metabolic disturbances, hyperandrogenism and infertility. New therapy concepts are warranted.
- Conditions
- Polycystic Ovary Syndrome, Healthy, Vitamin D Deficiency
- Trial name
- NCT01721915
- Testing
- Vitamin D supplementation
- Where
- Austria
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Myoma;Uterus, Vitamin D Deficiency
Vitamin D Levels And Myoma Uteri
Women with at least one uterine leiomyoma and polycystic ovary syndrome over 10 mm and women with normal ultrasonographic findings were included in the study.
- Conditions
- Myoma;Uterus, Vitamin D Deficiency, Polycystic Ovary
- Trial name
- NCT03871868
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Breast Cancer, Ovarian Cancer
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
In this study, the researchers want to learn more about Vigil and durvalumab in advanced women's cancers: 1) how much of Vigil in combination with durvalumab (MEDI4736) can be given with an acceptable level of side effects, 2)…
- Conditions
- Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT02725489
- Testing
- Vigil, Durvalumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mary Crowley Medical Research Center
Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Akt inhibitor MK2206 is a drug that may stop cancer cells from growing by blocking a protein called protein kinase B (AKT) inside the cell.
- Conditions
- Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01283035
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
- Trial name
- CYCAD-1 (NCT06188520)
- Testing
- AZD8421, Camizestrant, Ribociclib
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Breast Cancer, Lung Cancer
18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
The primary objective of the trial is to test the new radio tracer 18F-ASIS for PET imaging of tissue factor (TF) expression. The tracer has the potential of identifying tumors with high levels of TF expression, which is expected…
- Conditions
- Breast Cancer, Lung Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT03790423
- Testing
- Injection of 18F-ASIS, PET/CT scan
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cancer
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation.
- Trial name
- NCT00008359
- Testing
- caspofungin acetate, liposomal amphotericin B
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer, Ovarian Cancer
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of rIL-21 and Caelyx in cancer patients who have relapsed after, or have persistent disease after, first line therapy.
- Trial name
- NCT00523380
- Testing
- recombinant interleukin-21, caelyx (pegylated liposomal doxorubicin)
- Where
- 7 sites in France, Germany
- Volunteers
- 10 people
- Sponsor
- Novo Nordisk A/S
Ovarian, Breast
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
- Conditions
- Ovarian, Breast, Prostate, Pancreatic
- Trial name
- NCT01078662
- Testing
- olaparib
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 298 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
RATIONALE: Estrogen can cause the growth of ovarian epithelial cancer cells. Hormone therapy using fulvestrant may fight ovarian cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00617188
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
HOT: HIPEC in Ovarian Cancer as Initial Treatment
Community hospital based phase II (prospective randomized) study to evaluate the toxicity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly diagnosed, otherwise untreated, advanced…
- Conditions
- Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CRS/HIPEC (NCT02124421)
- Testing
- Cytoreductive Surgery (CRS), Adjuvant Chemotherapy, Questionnaire
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mercy Medical Center
Polycystic Ovary Syndrome
Inositol Treatment in Different Type of PCOS Phenotype
Evaluation of the efficacy of inositol treatment in women with PCOS in relation to the phenotype (according to the Rotterdam Criteria)
- Trial name
- NCT05678114
- Testing
- Myo-inositol
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Lo.Li.Pharma s.r.l
Gynecologic Cancer, Gynecologic Neoplasm
Patient-Reported Outcomes Among Women Wtih Gynecological Cancer (The CONNECT Study)
Systematic nurse-led consultations based on electronic patient-reported outcomes (ePRO) will be tested among women with ovarian - and endometrial cancer receiving first-line chemotherapy.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasm, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT04945187
- Testing
- Nurse-led consultations based on electronic patient-reported outcomes
- Where
- Denmark
- Volunteers
- 94 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558).
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only)
- Trial name
- NCT02335918
- Testing
- Combination of varlilumab and nivolumab
- Where
- 19 sites in United States
- Volunteers
- 175 people
- Sponsor
- Celldex Therapeutics
Ovarian Cancer
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
This single arm study evaluated the efficacy and safety of first-line chemotherapy with carboplatin and dose-dense weekly paclitaxel plus bevacizumab (Avastin) in participants with epithelial ovarian, fallopian tube, or primary…
- Trial name
- NCT00937560
- Testing
- Bevacizumab, Paclitaxel, Carboplatin
- Where
- 55 sites in Brazil, France and 7 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Advanced Breast Cancer, Early Breast Cancer
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.
- Trial name
- NCT07310420
- Testing
- ZOLADEX
- Where
- 26 sites in United States
- Volunteers
- 176 people
- Sponsor
- TerSera Therapeutics LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.